- AutorIn
- Maik Friedrich
- Karolin Wiedemann
- Kristin Reiche
- Sven-Holger Puppel
- Gabriele Pfeifer
- Ivonne Zipfel
- Stefanie Binder
- Ulrike Köhl
- Gerd A. Müller
- Kurt Engeland
- Achim Aigner
- Susanne Füssel
- Michael Fröhner
- Claudia Peitzsch
- Anna Dubrovska
- Michael Rade
- Sabina Christ
- Stephan Schreiber
- Jörg Hackermüller
- Jörg Lehmann
- Titel
- The Role of lncRNAs TAPIR-1 and -2 as Diagnostic Markers and Potential Therapeutic Targets in Prostate Cancer
- Zitierfähige Url:
- https://nbn-resolving.org/urn:nbn:de:bsz:15-qucosa2-846938
- Quellenangabe
- Cancers
Erscheinungsjahr: 2020
Jahrgang: 12
Heft: 5
E-ISSN: 2072-6694
Artikelnummer: 1122 - Erstveröffentlichung
- 2020
- Abstract (EN)
- In search of new biomarkers suitable for the diagnosis and treatment of prostate cancer, genome-wide transcriptome sequencing was carried out with tissue specimens from 40 prostate cancer (PCa) and 8 benign prostate hyperplasia patients. We identified two intergenic long non-coding transcripts, located in close genomic proximity, which are highly expressed in PCa. Microarray studies on a larger cohort comprising 155 patients showed a profound diagnostic potential of these transcripts (AUC~0.94), which we designated as tumor associated prostate cancer increased lncRNA (TAPIR-1 and -2). To test their therapeutic potential, knockdown experiments with siRNA were carried out. The knockdown caused an increase in the p53/TP53 tumor suppressor protein level followed by downregulation of a large number of cell cycle- and DNA-damage repair key regulators. Furthermore, in radiation therapy resistant tumor cells, the knockdown leads to a renewed sensitization of these cells to radiation treatment. Accordingly, in a preclinical PCa xenograft model in mice, the systemic application of nanoparticles loaded with siRNA targeting TAPIR-1 significantly reduced tumor growth. These findings point to a crucial role of TAPIR-1 and -2 in PCa.
- Andere Ausgabe
- Link zur Erstveröffentlichung
Link: https://doi.org/10.3390/cancers12051122 - Freie Schlagwörter (EN)
- lncRNA; prostate cancer; diagnostic marker; therapeutic target; p53; cell cycle arrest; radiation resistance
- Klassifikation (DDC)
- 610
- Verlag
- MDPI, Basel
- Version / Begutachtungsstatus
- publizierte Version / Verlagsversion
- URN Qucosa
- urn:nbn:de:bsz:15-qucosa2-846938
- Veröffentlichungsdatum Qucosa
- 13.04.2023
- Dokumenttyp
- Artikel
- Sprache des Dokumentes
- Englisch
- Lizenz / Rechtehinweis
- CC BY 4.0